DOXAZOSIN AND MELOXICAM COMBINATION THERAPY FOR BPH TREATMENT WITH LUTS
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
Abstract
Objective: To compare the efficacy of combination therapy of 4 mg doxazosin + 15 mg meloxicam with 4 mg doxazosin single therapy for benign prostate hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS). Materials & Methods: A prospective, randomized and double blind study with total of 22 BPH patients with LUTS were randomized to receive 4 mg doxazosin + placebo once daily for 6 weeks or a combination of 4 mg doxazosin + 15 mg meloxicam once daily for 6 weeks. Inclusion criteria included IPSS ≥ 8, age > 50 years, prostate blood flow grade II. Therapeutic efficacy was assessed by comparing changes in IPSS, maximal urinary flow (Q-max) and changes in prostate blood flow between baseline and immediately after 6 weeks of therapy. Results: There was no significant difference in IPSS change between the two treatment groups (delta IPSS 4 ± 1.1 versus 3.7 ± 1.5, p = 0.630). There was a significant difference in Q-max changes between the two groups (delta Q-max 4 ± 1.5 versus 2.1 ± 0.7, p < 0.001). In group therapied with 4 mg doxazosin + 15 mg meloxicam prostate blood flow decreased from grade II to grade I in 9 of 11 patients (81%). Whereas, in the treatment group of 4 mg doxazosin + placebo no reduction was found in prostate blood flow. Conclusion: Combination therapy of 4 mg doxazosin + 15 mg meloxicam once daily for 6 weeks is better than 4 mg doxazosin therapy alone in improving Q-max and decreasing prostate blood flow in BPH patients with LUTS.Keywords: Benign prostate hyperplasia, inflammation, COX-2 inhibitors.
##plugins.themes.bootstrap3.article.details##
Kirby R, Lepor H. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Walsh PC et al. Campbell’s Urology, 9th ed. 2007; 87.
Silverio FD, Gentile V, Matteis AD, Mriotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol. 2003; 43: 164–75.
Nicolas B, Gustavo DLR, Chandan V, Jones R, Sunheimer R, Threatte G, et al. Evaluation of prostatitis in autopsied prostates – is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol. 2008; 179: 1736-40.
Sciarra A, Silverio FD, Salciccia S, Maria A, Gomez A, Gentilucci A, et al. Inflammation and chronic prostatic diseases: Evidence for a Link? Eur Urol. 2007; 52: 964-72.
Kim BH, Kim CI, Chang HS, Choe MS, Jung HR, Kim DY, et al. Cyclooxygenase-2 over expression in chronic inflammation associated with benign prostatic hyperplasia: Is it related to apoptosis and angiogenesis of prostate cancer? Korean Journal of Urology. 2011; 52: 253-9.
Hamid AR, Umbas R, Mochtar CA. Recent role of inflammation in prostate diseases: Chemoprevention development opportunity. Acta Med Indonesia-Indones J Intern Med. 2011; 43(1): 59-65.
Cho INR, Keener TS, Nghiem HV, Winter T, Krieger JN. Prostate blood flow characteristics in the chronic prostatitis/pelvic pain syndrome. J Urol. 2000; 163: 1130-3.
Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, et al. Expression of cyclooxygenase- 1 and cyclooxygenase-2 in the human prostate. Urology. 2000; 56: 671-6.
Setiawati A. Farmakologi klinik, Dalam: Ganiswara SG: Farmakologi dan Terapi. Edisi 4. Gaya Baru Jakarta; 1998. p. 811-9.
Akan H, Basar M, Dalva L, Basar H. The early effect of doxazosin on benign prostatic hyperplasia. Arch Ital Urol Androl. 1998; 70(1): 41-4.
Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms, An Abstract. Urology. 2009; 74: 431-5.